HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced on [date] that it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The offering is subject to market conditions, and the final size and terms have not yet been determined. The company intends to use the net proceeds to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its artificial intelligence capabilities, and support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as sole bookrunner for the offering.
This capital raise comes shortly after HeartBeam received FDA clearance for its 12-lead ECG synthesis software in December 2025, following the clearance for arrhythmia assessment in December 2024. The company's platform technology is designed to collect ECG signals in 3D from three non-coplanar directions using a cable-free device, synthesizing them into a 12-lead ECG. This innovation aims to enable portable devices that can be used outside medical facilities, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. HeartBeam holds over 20 issued patents related to its technology.
The offering is a strategic move to accelerate the adoption of HeartBeam's technology in the cardiac care market. The funds will support the commercialization of the synthesized ECG system, which has the potential to expand access to advanced cardiac monitoring. Additionally, the company plans to invest in AI capabilities to enhance the analytical power of its platform. The extended-wear patch and heart attack detection initiatives are also key areas of focus, addressing unmet needs in continuous monitoring and early detection of critical cardiac events.
For more details on the company's cleared indications for use, visit HeartBeam's indications page. The full press release is available at this link.
